Hydronidone

Hydronidone

SCHEMBL143564

Cc1ccc(=O)n(-c2ccc(O)cc2)c1

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.67
KDM4E B2RXH2 3/20 0.67
CYP1A2 P05177 1/20 0.67
HPGD P15428 1/20 0.67
BLM P54132 1/20 0.67
HSD17B10 Q99714 1/20 0.67
MAPK14 Q16539 5/20 0.50
ACHE P22303 1/20 0.44
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
COMT P21964 1/20 0.41
POLB P06746 1/20 0.41
PTGS1 P23219 1/20 0.40
HSP90AA1 P07900 1/20 0.39
PKM P14618 1/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL356681 0.90 ALDH1A1 (0.80) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL3970272 0.88 ALDH1A1 (0.77) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL147877 0.81 ALDH1A1 (0.67) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL9892413 0.81 ALDH1A1 (0.67) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL3307167 0.81 ALDH1A1 (0.67) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL3302369 0.81 ALDH1A1 (0.67) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL3975362 0.81 ALDH1A1 (0.67) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL10059376 0.80 HSD17B10 (0.61) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL10059326 0.80 KDM4E (0.61) ALDH1A1KDM4ECYP1A2HPGDBLM
Pirfenidone SCHEMBL4708 0.80 KDM4E (1.00) ALDH1A1KDM4ECYP1A2HPGDBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12465605-B2 Methods and materials for gender-dependent treatment of cardiovascular dysfunction MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2025-11-11 US claimed
WO-2025051889-A1 ANTI PD-L2 ANTIBODIES FOR USE IN TREATING FIBROTIC DISEASES REJUVERON SENESCENCE THERAPEUTICS AG (CH) 2025-03-13 WO claimed
US-20240277682-A1 PHARMACEUTICAL HYDRONIDONE FORMULATIONS FOR DISEASES GYRE THERAPEUTICS, INC. 2024-08-22 US claimed
EP-4326265-A1 PHARMACEUTICAL HYDRONIDONE FORMULATIONS FOR DISEASES Gyre Therapeutics, Inc. (US) 2024-02-28 EP claimed
WO-2022221988-A1 PHARMACEUTICAL HYDRONIDONE FORMULATIONS FOR DISEASES SHANGHAI GENOMICS, INC. (CN) 2022-10-27 WO claimed
US-20140249347-A1 USE OF PYRIDONE DERIVATIVES IN THE PREVENTION OR TREATMENT OF TISSUE OR ORGAN TOXICITY INDUCED BY CYTOTOXIC AGENTS AND RADIATION SHANGHAI GENOMICS, INC. (CN) 2014-09-04 US claimed
US-8022087-B2 Derivatives of pyridone and use thereof Shangai Genomics, Inc. (CN) 2011-09-20 US claimed
US-20110123495-A1 DERIVATIVES OF PYRIDONE AND USE THEREOF CATALYST BIOSCIENCES, INC. 2011-05-26 US claimed
US-20080161361-A1 e.g. 5-methyl-1-(4-hydroxylphenyl)-2-(1H)-pyridone; pirfenidone derivatives; enhancing therapeutic efficacy of cytotoxic agent, immunosuppressant, and radiation therapy; fibrosis of the kidney or lung, radiation pneumonitis, interstitial pneumonia; cancer: lung, bone marrow, breast, colon, pancreas CATALYST BIOSCIENCES, INC. 2008-07-03 US claimed
EP-4747359-A2 HUMAN VASCULARIZED INTEGRATED ORGAN SYSTEM AND APPLICATIONS THEREOF 3D Systems, Inc. (US) 2026-05-27 EP disclosed
US-20260138998-A1 GLP-1 RECEPTOR AGONISTS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-05-21 US disclosed
US-20260137696-A1 Compositions Comprising an Inhibitor of Galectin-3 UNIVERSITY OF LIVERPOOL (GB) 2026-05-21 US disclosed
EP-4739319-A1 COMPOSITIONS COMPRISING AN INHIBITOR OF GALECTIN-3 University of Liverpool (GB) 2026-05-13 EP disclosed
EP-4739296-A1 COMPOSITIONS COMPRISING AN INHIBITOR OF GALECTIN-3 University of Liverpool (GB) 2026-05-13 EP disclosed
WO-2007053685-A2 METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS INTERMUNE, INC. (US) 2007-05-10 WO disclosed
US-20070049624-A1 Derivatives of pyridone and the use of them CATALYST BIOSCIENCES, INC. 2007-03-01 US disclosed
US-20070049624-A1 Derivatives of pyridone and the use of them CATALYST BIOSCIENCES, INC. 2007-03-01 US disclosed
US-20070049624-A1 Derivatives of pyridone and the use of them CATALYST BIOSCIENCES, INC. 2007-03-01 US disclosed
CN-1878757-A Pyridone derivatives and uses thereof SHANGHAI GENOMICS INC (CN) 2006-12-13 CN disclosed
EP-1683788-A1 THE DERIVATIVES OF PYRIDONE AND THE USE OF THEM Shanghai Genomics, Inc. (CN) 2006-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249347-A1 USE OF PYRIDONE DERIVATIVES IN THE PREVENTION OR TREATMENT OF TISSUE OR ORGAN TOXICITY INDUCED BY CYTOTOXIC AGENTS AND RADIATION PLPBP, PNPO, PIR ALDH1A1 338/4885KDM4E 2486/4885CYP1A2 350/4885
US-20260138998-A1 GLP-1 RECEPTOR AGONISTS AND METHODS OF USE GLP1R, GIPR, GPR119 ALDH1A1 2405/4885KDM4E 2314/4885CYP1A2 2666/4885
US-20110123495-A1 DERIVATIVES OF PYRIDONE AND USE THEREOF PNPO, PDXK, PLPBP ALDH1A1 185/4885KDM4E 1239/4885CYP1A2 17/4885
US-20080161361-A1 e.g. 5-methyl-1-(4-hydroxylphenyl)-2-(1H)-pyridone; pirfenidone derivatives; enhancing therapeutic efficacy of cytotoxic agent, immunosuppressant, and radiation therapy; fibrosis of the kidney or lung, radiation pneumonitis, interstitial pneumonia; cancer: lung, bone marrow, breast, colon, pancreas PIR, PDXK, BRCA1 ALDH1A1 1541/4885KDM4E 302/4885CYP1A2 964/4885
US-20070049624-A1 Derivatives of pyridone and the use of them PDXK, PNPO, PLPBP ALDH1A1 206/4885KDM4E 995/4885CYP1A2 33/4885
US-20240277682-A1 PHARMACEUTICAL HYDRONIDONE FORMULATIONS FOR DISEASES HYPK, SLC10A1, SYMPK ALDH1A1 1427/4885KDM4E 4547/4885CYP1A2 855/4885
US-20260137696-A1 Compositions Comprising an Inhibitor of Galectin-3 LGALS3, LGALS1, LGALS2 ALDH1A1 2477/4885KDM4E 3734/4885CYP1A2 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.